{"title":"Metabolic burden is independently and linearly associated with lower testosterone levels: evidence from NHANES.","authors":"Yavuz Güler","doi":"10.1515/hmbci-2026-0021","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Testosterone deficiency and metabolic dysfunction frequently coexist in aging men; however, whether metabolic impairment is associated with a progressive decline in testosterone across the metabolic spectrum remains unclear.</p><p><strong>Methods: </strong>We analyzed 2,192 U.S. men aged ≥40 years from the National Health and Nutrition Examination Survey (NHANES). Metabolic burden was assessed using the triglyceride-glucose (TyG) index. Survey-weighted linear regression models were used to evaluate the association between TyG and log-transformed total testosterone after adjustment for age, HDL cholesterol, diabetes, and smoking. Dose-response relationships were further examined using quartiles and restricted cubic spline analyses.</p><p><strong>Results: </strong>Higher TyG levels were independently associated with lower testosterone concentrations. In fully adjusted models, each 1-unit increase in TyG was associated with an approximately 12 % decrease in testosterone (p<0.001). Compared with the lowest TyG quartile, men in the highest quartile had approximately 19 % lower testosterone levels. Spline analysis demonstrated a consistent inverse association without significant nonlinearity (p for nonlinearity=0.21), supporting a graded and continuous relationship across the metabolic spectrum.</p><p><strong>Conclusions: </strong>Higher metabolic burden was independently associated with lower total testosterone levels in middle-aged and older men. However, due to the cross-sectional design and absence of SHBG/free testosterone measurements, these findings should be interpreted cautiously and require confirmation in longitudinal studies.</p>","PeriodicalId":13224,"journal":{"name":"Hormone Molecular Biology and Clinical Investigation","volume":" ","pages":"123-129"},"PeriodicalIF":1.9000,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Molecular Biology and Clinical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/hmbci-2026-0021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Testosterone deficiency and metabolic dysfunction frequently coexist in aging men; however, whether metabolic impairment is associated with a progressive decline in testosterone across the metabolic spectrum remains unclear.
Methods: We analyzed 2,192 U.S. men aged ≥40 years from the National Health and Nutrition Examination Survey (NHANES). Metabolic burden was assessed using the triglyceride-glucose (TyG) index. Survey-weighted linear regression models were used to evaluate the association between TyG and log-transformed total testosterone after adjustment for age, HDL cholesterol, diabetes, and smoking. Dose-response relationships were further examined using quartiles and restricted cubic spline analyses.
Results: Higher TyG levels were independently associated with lower testosterone concentrations. In fully adjusted models, each 1-unit increase in TyG was associated with an approximately 12 % decrease in testosterone (p<0.001). Compared with the lowest TyG quartile, men in the highest quartile had approximately 19 % lower testosterone levels. Spline analysis demonstrated a consistent inverse association without significant nonlinearity (p for nonlinearity=0.21), supporting a graded and continuous relationship across the metabolic spectrum.
Conclusions: Higher metabolic burden was independently associated with lower total testosterone levels in middle-aged and older men. However, due to the cross-sectional design and absence of SHBG/free testosterone measurements, these findings should be interpreted cautiously and require confirmation in longitudinal studies.
期刊介绍:
Hormone Molecular Biology and Clinical Investigation (HMBCI) is dedicated to the provision of basic data on molecular aspects of hormones in physiology and pathophysiology. The journal covers the treatment of major diseases, such as endocrine cancers (breast, prostate, endometrium, ovary), renal and lymphoid carcinoma, hypertension, cardiovascular systems, osteoporosis, hormone deficiency in menopause and andropause, obesity, diabetes, brain and related diseases, metabolic syndrome, sexual dysfunction, fetal and pregnancy diseases, as well as the treatment of dysfunctions and deficiencies. HMBCI covers new data on the different steps and factors involved in the mechanism of hormone action. It will equally examine the relation of hormones with the immune system and its environment, as well as new developments in hormone measurements. HMBCI is a blind peer reviewed journal and publishes in English: Original articles, Reviews, Mini Reviews, Short Communications, Case Reports, Letters to the Editor and Opinion papers. Ahead-of-print publishing ensures faster processing of fully proof-read, DOI-citable articles.